CM355

PreclinicalSmall molecule

BBeijing InnoCare Pharma Tech Co., Ltd.

CM355 is one of 75 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

LymphomaActive, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT07104344

Phase 1/2Active, not recruiting

Lymphoma

NCT05210868

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Active, not recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1/2·NCT05210868·184 enrolled

Systemic Lupus Erythematosus1 trial

Study of CM355 in Patients With Systemic Lupus Erythematosus

Not yet recruiting·SSecond Xiangya Hospital of Central South University·N/A·NCT07104344·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CM355. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CM355 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CM355. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing InnoCare Pharma Tech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBeijing InnoCare Pharma Tech Co., Ltd.

CM355

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Lymphoma1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News